The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 25.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (1 analysts) rates it none, with a mean price target of $2.
PetMed Express, Inc.
PETS · Nasdaq · USD · Market cap $46M
FAIL · Does not pass the screenPrice as of 26 Oct 2026Daily close, not a live quote
Screened 2026-10-26 · the tape above runs as of 12:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price1.16 USD at the 26 Oct 2026 close
- Ethical screenDoes not pass
- Last reviewed26 Oct 2026 (3 days ago)
A summary of the dated readings below, not a live quote and not advice.
What this means: price 1.16 against the desk's fair-value range, over the last year.
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markdown label.
PetMed Express, Inc. holds its Markdown at $1.16. Consolidating, no directional conviction, held for 70 days.
| Phase | Markdown · caution |
| Quantitative state | Consolidating, no directional conviction, held for 70 days |
| Price at the screen | $1.16 |
| Valuation | 0.00 trailing · -71.92 forward price to earnings |
| Values screen | FAIL |
Five Screens, Shown in Full
Does not pass. Cash ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 1.41% | Below 33% | Interest-bearing debt is just 1.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 58.29% | Below 33% | Interest-bearing cash and securities are 58.3% of assets, above the one-third limit. | Fail |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.29% | Below 5% | Only 0.3% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
PetMed Express,'s business is fine, but its cash and interest-bearing securities are about 58% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PETS's ethical verdict changes
Today PETS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
| Forward P/E | -71.9x |
| Trailing P/E | 0.0x |
| EPS, trailing | -3.11 |
| EPS, forward | -0.03 |
| Revenue growth | -21.7%revenue is shrinking |
| Profit margin | -34.7%currently unprofitable |
| Return on equity | -100.6%not currently earning a positive return on equity |
| Debt to equity | 0.02minimal debt: a conservative balance sheet |
| Market cap | $46M |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradePETS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (1 analysts) rates it none, with a mean price target of $2.
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (1 analysts) rates it none, with a mean price target of $2.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (1 analysts) rates it none, with a mean price target of $2.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 59%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (1 analysts) rates it none, with a mean price target of $2.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-30 | FULGONI GIAN M | Director | 33,846 | · | |
| 2025-10-30 | MENNEN JUSTIN L. | Director | 33,846 | · | |
| 2025-10-30 | LACAMP JAMES | Director | 34,866 | · | |
| 2025-10-30 | SOLIVAN LEAH A. | Director | 33,846 | · | |
| 2025-10-30 | BATUSHANSKY PETER | Director | 33,846 | · | |
| 2025-10-30 | KRULIK DOUGLAS | Chief Financial Officer | 20,000 | · | |
| 2025-09-09 | KRULIK DOUGLAS | Officer | 10,000 | · | |
| 2025-08-13 | SILVERCAPE INVESTMENTS LTD. | Beneficial Owner of more than 10% of a Class of Security | 101,000 | $320,170 | |
| 2025-08-01 | SILVERCAPE INVESTMENTS LTD. | Beneficial Owner of more than 10% of a Class of Security | 118,200 | $379,422 | |
| 2025-07-21 | NINA CAPITAL HOLDINGS INC | Beneficial Owner of more than 10% of a Class of Security | 25,000 | $87,425 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $2.26 | -23.9% | · | $761 | -23.9% |
| 2 months | $2.30 | -25.2% | · | $748 | -25.2% |
| 3 months | $2.43 | -29.2% | · | $708 | -29.2% |
| 6 months | $2.98 | -42.3% | · | $577 | -42.3% |
| 1 year | $4.19 | -59.0% | · | $411 | -59.0% |
| 2 years | $4.20 | -59.1% | · | $410 | -59.1% |
| 3 years | $14.61 | -88.2% | $0.30 | $138 | -86.2% |
| 5 years | $28.70 | -94.0% | $2.70 | $154 | -84.6% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PETS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.